GSA Capital Partners’s Design Therapeutics DSGN Stock Holding History

GSA Capital Partners’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$149K	Buy	+10,328	New	+$129K	0.01%	1584
2025 Q3	–	Sell	-59,975	Closed	-$202K	–	1751
2025 Q2	$202K	Sell	59,975 -12,174	-17%	-$45.6K	0.01%	1503
2025 Q1	$278K	Sell	72,149 -46,179	-39%	-$220K	0.03%	1205
2024 Q4	$730K	Sell	118,328 -55,416	-32%	-$321K	0.05%	619
2024 Q3	$935K	Sell	173,744 -36,209	-17%	-$170K	0.07%	511
2024 Q2	$703K	Sell	209,953 -6,394	-3%	-$24.9K	0.05%	753
2024 Q1	$872K	Buy	216,347 +144,055	+199%	+$385K	0.07%	533
2023 Q4	$192K	Buy	72,292 +28,711	+66%	+$65.8K	0.02%	1331
2023 Q3	$103K	Sell	43,581 -194,619	-82%	-$908K	0.01%	1383
2023 Q2	$1.5M	Buy	238,200 +140,300	+143%	+$859K	0.15%	140
2023 Q1	$565K	Buy	97,900 +84,281	+619%	+$630K	0.06%	630
2022 Q4	$140K	Buy	+13,619	New	+$185K	0.02%	1259

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's DSGN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Design Therapeutics (DSGN) in Q2 2026: 10,328 shares worth $149K. The stake represents 0.01% of the portfolio and ranks #1584 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in DSGN as recently as Q2 2025.

GSA Capital Partners first reported a position in DSGN in Q4 2022 and has held it in 12 quarters since. The position peaked at $1.5M in Q2 2023. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

GSA Capital Partners held 10,328 shares of Design Therapeutics worth $149K as of Q2 2026.
Design Therapeutics was a new GSA Capital Partners position in Q2 2026.
Design Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1584 holding.
GSA Capital Partners first reported a position in Design Therapeutics in Q4 2022 and has held it in 12 quarters since.
GSA Capital Partners's Design Therapeutics position peaked at $1.5M in Q2 2023.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.